- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Intermittent Degarelix Effective With Less Metabolic Syndrome Than Hormone Agonists, Studies Suggest
May 20th 2014, 10:15am
Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC
May 20th 2014, 8:20am
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.
Dr. Crawford on Intermittent Androgen Deprivation With Degarelix
May 20th 2014, 6:26am
E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.
ED Therapy May Preserve Function, Penile Length After Prostatectomy
May 19th 2014, 12:16pm
Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.
Testicular Self-Examination Cost-Effective Compared with Missed Advanced Cancer
May 19th 2014, 6:01am
Testicular self-examination remains highly cost-effective despite a negative recommendation from the United States Preventive Services Task Force (USPSTF), a cost-utility analysis suggested.
In Dog Study, Prostate Cancer Found With a Whiff and a Woof
May 19th 2014, 5:31am
When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.
Dr. Aberger Discusses a Cost Analysis of Testicular Self-Examinations
May 18th 2014, 11:31am
Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.
Social Media Vital in Marketing Large Urology Practices
May 18th 2014, 7:57am
In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.
Physical Activity Linked to Lower Risk of Death from Bladder Cancer
May 18th 2014, 7:19am
Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.
Active Surveillance Is No Threat to Prostate Cancer Cure-So Far
May 18th 2014, 6:32am
Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.
Dr. Mirza on Hematuria and a Bladder Cancer Diagnosis
May 17th 2014, 9:24am
Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.
Dr. Rhee Discusses Workplace Violence in Urology Practices
May 17th 2014, 7:48am
Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.
As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes
May 14th 2014, 1:10pm
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS
May 14th 2014, 1:05pm
The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.
For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality
May 14th 2014, 1:00pm
Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.
Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests
May 14th 2014, 1:00pm
A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.
AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC
May 14th 2014, 1:00pm
The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.
Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death
April 9th 2014, 8:44am
A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
April 7th 2014, 12:07pm
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Dr. Flynn on CDK Inhibitors for the Treatment of CLL
April 7th 2014, 12:02pm
Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).